



KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002
Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, **Email:** investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

03rd August, 2023

**To,
BSE Limited
Listing Department,
Phiroz Jeejeebhoy Tower,
25th Floor, Dalal Street,
Mumbai-400 001**

Ref.: BSE Scrip Code – 531960

Dear Sir/Madam,

Subject: Submission of Unaudited Financial Results and Limited Review Report thereon for the first quarter ended 30th June, 2023

With reference to above and pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015 (as amended), find enclosed the Unaudited Financial Results for the first quarter ended 30th June, 2023, prepared in accordance with Regulation 33 of the SEBI (LODR) Regulations, 2015 and Companies (Indian Accounting Standards) Rules, 2015 (IND-AS), along with the Limited Review Report thereon as received from Statutory Auditors of the Company. The same has been considered, approved and taken on record by the Board of Directors at their meeting held on Thursday, 03rd August, 2023.

Further, pursuant to Regulation 46 & 47 of SEBI (LODR) Regulations, 2015, the said result will be uploaded on the website of the Company and will be duly published in the required newspapers within prescribed timeframe.

You are requested to acknowledge and update the same in your records.

**Thanking you.
Yours faithfully,
For, KASHYAP TELE-MEDICINES LIMITED**

**PARITOSH TRIVEDI
COMPANY SECRETARY**

Encl: As above



SAREMAL & CO

Chartered Accountants

CA Saremal Shah (Bcom, FCA); CA Pravin Lavana (Bcom, LLB, FCA)

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE QUARTERLY UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30TH JUNE, 2023 OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

To
The Board of Directors,
KASHYAP TELE-MEDICINES LIMITED
AHMEDABAD

1. We have reviewed the accompanying statement of Un-audited Financial Results of **KASHYAP TELE-MEDICINES LIMITED** (the Company) for the first quarter ended 30th June, 2023 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended (the 'Listing Regulations'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29th March, 2019 and SEBI Circular No. CIR/CFD/CMD1/80/2019 dated 19th July, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Statement on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our Conclusion is not modified in respect of this matter.

For SAREMAL & CO.
CHARTERED ACCOUNTANTS



PRAVIN LAVANA
(PARTNER)
MEMBERSHIP NO.: 037180
FIRM REGISTRATION NO.: 109281W
UDIN No. 23037180BGWYDE2657

Ahmedabad, 03rd August, 2023

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai – 400002
 Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006
 Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com
 Website: www.kashyaptele-medicines.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30TH JUNE, 2023

(As per Regulation 33 of SEBI (LODR) Regulations, 2015 & Schedule III Companies Act, 2013 read with IND-AS)

S.No.	Particulars	Quarter Ended			Year ended
		30/06/2023	31/03/2023	30/06/2022	31/03/2023
		(Unaudited)	(Refer Note 3)	(Unaudited)	(Audited)
I	Revenue from operations	4.65	3.85	5.30	19.65
II	Other Income	0.00	0.00	0.00	0.02
III	Total Revenue (I + II)	4.65	3.85	5.30	19.67
IV	Expenses				
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade				0.00
		0.00	0.00	0.00	
	(d) Employee benefits expense	2.70	2.73	2.55	10.20
	(e) Finance Cost	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00
	(g) Other expenses	1.78	1.73	1.98	9.05
	Total expenses	4.48	4.46	4.53	19.25
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	0.17	(0.61)	0.77	0.42
VI	Exceptional items	0.00	0.00	0.00	0.00
VII	Profit before extraordinary items and tax (V - VI)	0.17	(0.61)	0.77	0.42
VIII	Extraordinary items	0.00	0.00	0.00	0.00
IX	Profit/(Loss) Before Tax (VII- VIII)	0.17	(0.61)	0.77	0.42
X	Tax expense :-				
	(a) Current tax	0.04	(0.15)	0.19	0.11
	(b) Tax relating to previous period	0.00	0.00	0.00	0.00
	(c) Deferred tax	0.00	0.00	0.00	0.00
	Total Tax Expense	0.04	(0.15)	0.19	0.11
XI	Profit / (Loss) for the period from continuing operations (IX - X)	0.13	(0.46)	0.58	0.31
XII	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
XIII	Tax expense of discontinuing operations	0.00	0.00	0.00	0.00
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00
XV	Profit / (Loss) for the period (XI + XIV)	0.13	(0.46)	0.58	0.31
XVI	Share of profit / (loss) of Associates	N.A.	N.A.	N.A.	N.A.
XVII	Minority interest	N.A.	N.A.	N.A.	N.A.
XVIII	Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates	0.13	(0.46)	0.58	0.31
XIX	Other Comprehensive Income				
	A. Items that will be/will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
	Total comprehensive income for the period (XVIII+XIX)	0.13	(0.46)	0.58	0.31
XX	Paid-up equity share capital (Face Value of Rs. 1/- each)	477.22	477.22	477.22	477.22
XXI	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	(410.24)
XXII	Earnings per equity share:				
	(a) Basic	0.000	(0.001)	0.001	0.001
	(b) Diluted	0.000	(0.001)	0.001	0.001

Notes:

- The above Unaudited Financial Results of the company for the quarter ended on 30th June, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors in the Meeting held on 03rd August, 2023.
- The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Ind As') from 1st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and discloses the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended).
- The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year upto 31st March, 2023 and the unaudited published year-to-date figures upto 31st December, 2022 being the date of the end of the third quarter of the financial year.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results for the quarter ended on 30th June, 2023 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
- A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).
- The company is engaged in single segment therefore has only one reportable segment in accordance with Ind AS 108 'Operating Segments'.
- Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.

Place : Ahmedabad
Date : 03rd August, 2023



For and on behalf of Board of Directors of
Kashyap Tele - Medicines Limited



Raghav Agrawal
Director & CFO
DIN: 02264149